NextCure (NXTC) Stock Skyrockets 300% Following $320 Million Avere Therapeutics Merger Agreement
Key Takeaways Shares of NextCure (NXTC) soared more than 300% Tuesday following the announcement of an all-stock combination with private biotech firm Avere Therapeutics A simultaneous $320 m








